SEARCH

SEARCH BY CITATION

References

  • 1
    El-Serag HB, Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000; 160: 3227-3230.
  • 2
    Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
  • 3
    Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis 2010; 30: 61-74.
  • 4
    Marrero JA, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, et al. Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort. HEPATOLOGY 2005; 41: 707-716.
  • 5
    Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006; 44: 723-731.
  • 6
    Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda,CLIP, and BCLC staging systems in a single Italian centre. Gut 2005; 54: 411-418.
  • 7
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. HEPATOLOGY 2011; 53: 1020-1022.
  • 8
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. HEPATOLOGY 2003; 37: 429-442.
  • 9
    National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Hepatobiliary guidelines. V.2.2010. www.nccn.org/professionals/physician_gls/PDF/hepatobiliary.pdf last accessed June 8th, 2011.
  • 10
    Jelic S, Sotiropoulos GC, on behalf of the ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2010;( 21 Suppl. 5): v59-v64.
  • 11
    Kennedy A, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of 90Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 2004; 60: 1552-1563.
  • 12
    Sangro B, D'Avola D, Iñarrairaegui M, Prieto J. Transarterial therapies for hepatocellular carcinoma. Exp Opin Pharmacother 2011; 12: 1057-1073.
  • 13
    Sangro B, Bilbao JI, Boan J, Martinez-Cuesta A, Benito A, Rodriguez J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2006; 66: 792-800.
  • 14
    Geschwind JF, Salem R, Carr BI, Soulen MC, Thurston KG, Goin KA, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology 2004; 127: S194-S205.
  • 15
    Ettorre GM, Santoro R, Puoti C, Sciuto R, Carpanese L, Antonini M, et al. Short-term follow-up of radioembolization with yttrium-90 microspheres before liver transplantation: new perspectives in advanced hepatocellular carcinoma. Transplantation 2010; 90: 930-931.
  • 16
    Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. HEPATOLOGY 2008; 47: 71-81.
  • 17
    Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138: 52-64.
  • 18
    Iñarrairaegui M, Thurston KG, Arbizu J, Martinez-Cuesta A, Bilbao JI, Sangro B, et al. Radioembolization using 90Y resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010; 21: 1205-1212.
  • 19
    Goin JE, Salem R, Carr BI, Dancey JE, Soulen MC, Geschwind JF, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: factors associated with liver toxicities. J Vasc Interv Radiol 2005; 16: 205-213.
  • 20
    Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver Transpl 2004; 10: S107-S110.
  • 21
    Kennedy AS, McNeillie P, Dezarn WA, Nutting C, Sangro B, Wertman D, et al. Treatment parameters and outcome in 680 treatments of internal radiation with resin 90Y-microspheres for unresectable hepatic tumors. Int J Radiat Oncol Biol Phys 2009; 74: 1494-1500.
  • 22
    Sangro B, Gil-Alzugaray B, Rodriguez J, Sola I, Martinez-Cuesta A, Viudez A, et al. Liver disease induced by radioembolization of liver tumors: description and possible risk factors. Cancer 2008; 112: 1538-1546.
  • 23
    Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the Radioembolization Brachytherapy Oncology Consortium. Int J Radiat Oncol Biol Phys 2007; 68: 13-23.
  • 24
    Coldwell D, Sangro B, Wasan H, Salem R, Kennedy A. General selection criteria of patients for radioembolization of liver tumors: an international working group report. Am J Clin Oncol 2011; 34: 337-341.
  • 25
    Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
  • 26
    Bilbao JI, Reiser MF, eds. Liver Radioembolization with 90Y Microspheres. New York, NY: Springer Verlag; 2008.
  • 27
    Hill T, Lewicki P. Statistics: methods and applications: a comprehensive reference for science, industry, and data mining. Tulsa, OK: StatSoft, Inc.; 2006.
  • 28
    Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H. Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol 2010; doi:10.1097/COC.0b013e3181df0a50.
  • 29
    Kulik LM, Atassi B, Van Holsbeeck L, Souman T, Lewandowski RJ, Mulcahy MF, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 2006; 94: 572-586.
  • 30
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
  • 31
    Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, et al. Radioembolization results in longer time to progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140: 497-507.